Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.

Br J Cancer · 2012 · PMC3364117 · PMID 22538971

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a significant trendP =0.05actually significant

However, in the case of M65 ELISA, a significant trend towards higher levels in the EP group was recorded ( P =0.05 compared with PD and P =0.08 compared with SD, Mann–Whitney U test), indicating that in the OXi4503 cohort of patients, elevated pre-dose may relate to early disease progression.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.